Literature DB >> 23083512

Epidemiology and neuropsychiatric manifestations of Young Onset Parkinson's Disease in the United States.

A W Willis1, M Schootman, N Kung, B A Racette.   

Abstract

BACKGROUND: To determine the demographic distribution of Young Onset Parkinson's Disease (YOPD) in the United States and to quantify the burden of neuropsychiatric disease manifestations.
METHODS: Cross sectional study of 3,459,986 disabled Americans, aged 30-54, who were receiving Medicare benefits in the year 2005. We calculated race and sex distributions of YOPD and used logistic regression to compare the likelihood of common and uncommon psychiatric disorders between beneficiaries with YOPD and the general disability beneficiary population, adjusting for race, age, and sex.
RESULTS: We identified 14,354 Medicare beneficiaries with YOPD (prevalence = 414.9 per 100,000 disabled Americans). White men comprised the majority of cases (48.9%), followed by White women (34.7%), Black men (6.8%), Black women (5.0%), Hispanic men (2.4%), and Hispanic women (1.2%). Asian men (0.6%) and Asian women (0.4%) were the least common race-sex pairs with a YOPD diagnosis in this population (chi square, p < 0.001). Compared to the general population of medically disabled Americans, those with YOPD were more likely to receive medical care for depression (OR: 1.89, 1.83-1.95), dementia (OR: 7.73, 7.38-8.09), substance abuse/dependence (OR: 3.00, 2.99-3.01), and were more likely to be hospitalized for psychosis (OR: 3.36, 3.19-3.53), personality/impulse control disorders (OR: 4.56, 3.28-6.34), and psychosocial dysfunction (OR: 3.85, 2.89-5.14).
CONCLUSIONS: Young Onset Parkinson's Disease is most common among white males in our study population. Psychiatric illness, addiction, and cognitive impairment are more common in YOPD than in the general population of disabled Medicare beneficiaries. These may be key disabling factors in YOPD.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23083512      PMCID: PMC3562561          DOI: 10.1016/j.parkreldis.2012.09.014

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  26 in total

1.  Pathologic gambling in patients with Parkinson's disease.

Authors:  U Gschwandtner; J Aston; S Renaud; P Fuhr
Journal:  Clin Neuropharmacol       Date:  2001 May-Jun       Impact factor: 1.592

2.  Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences.

Authors:  Anette Schrag; Anna Hovris; David Morley; Niall Quinn; Marjan Jahanshahi
Journal:  Mov Disord       Date:  2003-11       Impact factor: 10.338

Review 3.  Diagnostic considerations in juvenile parkinsonism.

Authors:  Dominic C Paviour; Robert A H Surtees; Andrew J Lees
Journal:  Mov Disord       Date:  2004-02       Impact factor: 10.338

Review 4.  Quality of life and depression in Parkinson's disease.

Authors:  Anette Schrag
Journal:  J Neurol Sci       Date:  2006-06-21       Impact factor: 3.181

5.  A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender.

Authors:  R Mayeux; J Denaro; N Hemenegildo; K Marder; M X Tang; L J Cote; Y Stern
Journal:  Arch Neurol       Date:  1992-05

6.  Prospective prevalence of pathologic gambling and medication association in Parkinson disease.

Authors:  V Voon; K Hassan; M Zurowski; S Duff-Canning; M de Souza; S Fox; A E Lang; J Miyasaki
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

7.  Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study.

Authors:  M Shiba; J H Bower; D M Maraganore; S K McDonnell; B J Peterson; J E Ahlskog; D J Schaid; W A Rocca
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

8.  Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.

Authors:  A Schrag; Y Ben-Shlomo; R Brown; C D Marsden; N Quinn
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

9.  Age of disease onset influences cognition in Parkinson's disease.

Authors:  H L Katzen; B E Levin; M L Llabre
Journal:  J Int Neuropsychol Soc       Date:  1998-05       Impact factor: 2.892

10.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.

Authors:  Philippe Remy; Miroslava Doder; Andrew Lees; Nora Turjanski; David Brooks
Journal:  Brain       Date:  2005-02-16       Impact factor: 13.501

View more
  11 in total

Review 1.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 2.  Using Administrative Data to Examine Health Disparities and Outcomes in Neurological Diseases of the Elderly.

Authors:  Allison W Willis
Journal:  Curr Neurol Neurosci Rep       Date:  2015-11       Impact factor: 5.081

3.  Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment.

Authors:  Karen Curtin; Annette E Fleckenstein; Reid J Robison; Michael J Crookston; Ken R Smith; Glen R Hanson
Journal:  Drug Alcohol Depend       Date:  2014-11-16       Impact factor: 4.492

4.  Medicare Claims Data Underestimate Hallucinations in Older Adults With Dementia.

Authors:  Ali G Hamedani; Daniel Weintraub; Allison W Willis
Journal:  Am J Geriatr Psychiatry       Date:  2021-08-05       Impact factor: 4.105

5.  Real-World Prescription Patterns For Patients With Young-Onset Parkinson's Disease in China: A Trend Analysis From 2014 to 2019.

Authors:  Xiao-Qin Liu; Xiao-Yu Wang; Hui-Ming Shen; Wen-Yuan Pang; Ming-Kang Zhong; Chun-Lai Ma
Journal:  Front Pharmacol       Date:  2022-05-12       Impact factor: 5.988

6.  Hospital care for mental health and substance abuse conditions in Parkinson's disease.

Authors:  Allison W Willis; Dylan P Thibault; Peter N Schmidt; E Ray Dorsey; Daniel Weintraub
Journal:  Mov Disord       Date:  2016-12       Impact factor: 10.338

7.  Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder.

Authors:  Karen Curtin; Annette E Fleckenstein; Brooks R Keeshin; Deborah A Yurgelun-Todd; Perry F Renshaw; Ken R Smith; Glen R Hanson
Journal:  Neuropsychopharmacology       Date:  2018-09-12       Impact factor: 7.853

Review 8.  Using Medical Claims Analyses to Understand Interventions for Parkinson Patients.

Authors:  Bastiaan R Bloem; Jan H L Ypinga; Allison Willis; Colleen G Canning; Roger A Barker; Marten Munneke; Nienke M De Vries
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

9.  Enhancing Trial Delivery in Parkinson's Disease: Qualitative Insights from PD STAT.

Authors:  Angie A Kehagia; Tracie K North; Jane Grose; Alison N Jeffery; Laura Cocking; Rebecca Chapman; Camille Carroll
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

10.  Sparse feature learning for multi-class Parkinson's disease classification.

Authors:  Haijun Lei; Yujia Zhao; Yuting Wen; Qiuming Luo; Ye Cai; Gang Liu; Baiying Lei
Journal:  Technol Health Care       Date:  2018       Impact factor: 1.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.